DeSigN: connecting gene expression with therapeutics for drug repurposing and development

Abstract

BackgroundThe drug discovery and development pipeline is a long and arduous process that inevitably hampers rapid drug development. Therefore, strategies to improve the efficiency of drug development are urgently needed to enable effective drugs to enter the clinic. Precision medicine has demonstrated that genetic features of cancer cells can be used for predicting drug response, and emerging evidence suggest that gene-drug connections could be predicted more accurately by exploring the cumulative effects of many genes simultaneously.ResultsWe developed DeSigN, a web-based tool for predicting drug efficacy against cancer cell lines using gene expression patterns. The algorithm correlates phenotype-specific gene signatures derived from differentially expressed genes with pre-defined gene expression profiles associated with drug response data (IC50) from 140 drugs. DeSigN successfully predicted the right drug sensitivity outcome in four published GEO studies. Additionally, it predicted bosutinib, a Src/Abl kinase inhibitor, as a sensitive inhibitor for oral squamous cell carcinoma (OSCC) cell lines. In vitro validation of bosutinib in OSCC cell lines demonstrated that indeed, these cell lines were sensitive to bosutinib with IC50 of 0.8–1.2 μM. As further confirmation, we demonstrated experimentally that bosutinib has anti-proliferative activity in OSCC cell lines, demonstrating that DeSigN was able to robustly predict drug that could be beneficial for tumour control.ConclusionsDeSigN is a robust method that is useful for the identification of candidate drugs using an input gene signature obtained from gene expression analysis. This user-friendly platform could be used to identify drugs with unanticipated efficacy against cancer cell lines of interest, and therefore could be used for the repurposing of drugs, thus improving the efficiency of drug development.Electronic supplementary materialThe online version of this article (doi:10.1186/s12864-016-3260-7) contains supplementary material, which is available to authorized users.

Transcriptome-Guided Drug Repositioning

“…Drug repositioning opens new possibilities for the fast delivery of new treatment options by reducing the time and resources spent on drug development and testing [1,2]. Systematic analysis of concerted transcriptome changes in response to disease and drug action provides a useful concept in this field [63][64][65]. However, it is essential to consider gene expression changes on the whole transcriptome level and not only identify drug-target processes or genes to improve the predictive power of the method but also to understand how off-target genes may interfere with disease development, drug action or be related to the risk of adverse effects.…”

Integrative Omics for Informed Drug Repurposing: Targeting CNS Disorders

“…In such an instance, a connection with significant p-value and but low tau would suggest a promiscuous drug with non-unique connections, while those with high tau scores would suggest a drug more 1 specific to the disease signature. Several other approaches [50,51] and tools [52,53] exist to evaluate drug-drug and drug-disease similarity comparisons. A well-conceived article by Zhou et al provides a systematic evaluation of a variety of these approaches [54].…”

Analysis of Infected Host Gene Expression Reveals Repurposed Drug Candidates and Time-Dependent Host Response Dynamics for COVID-19

“…We and others [10][11][12][13][14][15][16] have utilized a systems-based approach that employs gene expression profiles of disease samples and drug-induced gene expression profiles from cell lines to discover new therapeutic candidates for diseases. The essential idea is to identify drugs that reverse the disease gene expression signature by suppressing the over-expressed disease genes and activating the repressed genes ( Figure 1A).…”